Armata Pharmaceuticals Inc

NYSE American: ARMP    
Share price (5/10/24): $2.86    
Market cap (5/10/24): $106 million

Underwriting Agreements Filter

EX-1.1
from S-1/A 36 pages [•] Shares of Common Stock Pre-Funded Warrants to Purchase [•] Shares of Common Stock and Warrants to Purchase [•] Shares of Common Stock Ampliphi Biosciences Corporation Underwriting Agreement
12/34/56
EX-1.1
from S-1/A 35 pages [•] Shares of Common Stock and Pre-Funded Warrants to Purchase [•] Shares of Common Stock Ampliphi Biosciences Corporation Underwriting Agreement
12/34/56
EX-1.1
from S-1/A 37 pages [ ] Shares of Common Stock Pre-Funded Warrants to Purchase [ ] Shares of Common Stock and Warrants to Purchase [ ] Shares of Common Stock Ampliphi Biosciences Corporation Underwriting Agreement
12/34/56
EX-1.1
from S-1/A 35 pages [ ] Shares of Common Stock and Warrants to Purchase [ ] Shares of Common Stock Ampliphi Biosciences Corporation Underwriting Agreement
12/34/56
EX-1
from SC 13G 1 page Joint Filing Agreement
12/34/56
EX-1.1
from SC 13G 1 page Joint Filing Agreement
12/34/56
EX-1.1
from 8-K ~20 pages 10,854,257 Shares Targeted Genetics Corporation Shares of Common Stock ($.01 Par Value) Placement Agent Agreement
12/34/56
EX-1
from SC 13D/A 1 page International Biotechnology Trust PLC By: /S/ Andrew Barker Title: Director Schroder Investment Management Limited By: /S/ John Spedding Title: Secretary /S/ Tom Daniel Tom Daniel /S/ Kate Bingham Kate Bingham /S/ Eva Haas Eva Haas
12/34/56
EX-1.9
from 8-K 1 page <page> Exhibit 1.9 First Amendment of Rights Agreement Subject to the Terms Hereof, Pursuant to Section 26 of the Rights Agreement, Dated as of October 17, 1996, by and Between Targeted Genetics Corporation (The "Company") and Chasemellon Shareholder Services (The "Rights Agreement"), the Company, by This First Amendment of Rights Agreement Dated July 21, 1999, Does Hereby Amend the Rights Agreement as Follows: Section 1 Is Hereby Amended to Add the Following Sentence at the End of the Definition of "Acquiring Person": Notwithstanding the Foregoing, Neither Elan International Services, Ltd. ("Eis") Nor Any Affiliate or Associate of Eis Shall Be Included Within the Definition of "Acquiring Person" by Virtue of the Acquisition by Eis of Shares of Common Stock, or Any Securities Convertible Into or Exchangeable for Shares of Common Stock, Pursuant to the Transactions Contemplated by the Securities Purchase Agreement, Dated July 21, 1999, Between the Company and Eis and the Convertible Promissory Note, Dated July 21, 1999, Issued by the Company to Eis (The "Transaction Securities"); Provided, However, Eis Shall Be Included Within the Definition of Acquiring Person to the Extent Eis, Either Alone or Together With All Affiliates and Associates of Eis, Including the Transaction Securities, Becomes the Beneficial Owner of 15% or More of the Common Stock Then Outstanding as the Result of Being or Becoming the Beneficial Owner of Common Stock Other Than the Transaction Securities. in Witness Whereof, the Company Has Executed This First Amendment to Rights Agreement as of the Date First Written Above. Targeted Genetics Corporation By: /S/ James A. Johnson James A. Johnson Vice President & Chief Financial Officer
12/34/56
EX-1.8
from 8-K ~10 pages Articles of Amendment, Filed With the State of Wa.
12/34/56
EX-1.7
from 8-K ~20 pages License Agreement Date July 21, 1999
12/34/56
EX-1.6
from 8-K ~50 pages License Agreement Date July 21, 1999
12/34/56
EX-1.5
from 8-K ~10 pages Convertible Promissory Note
12/34/56
EX-1.4
from 8-K ~50 pages Subscription, Joint Devel. & Oper. Agreement
12/34/56
EX-1.3
from 8-K ~5 pages Funding Agreement
12/34/56
EX-1.2
from 8-K ~10 pages Registration Rights Agreement
12/34/56
EX-1.1
from 8-K ~20 pages Securities Purchase Agreement
12/34/56
EX-1.6
from 8-K 1 page <page> Exhibit 1.6 November 23, 1998 Medeva Pharmaceuticals, Inc. 755 Jefferson Road Rochester, Ny 14623 Medeva PLC 10 St. James's Street London Sw1ef England Re: Common Stock Purchase Agreement (The "Agreement") Dated as of November 23, 1998 Among Targeted Genetics Corporation (The "Company"), Medeva Pharmaceuticals, Inc. ("Investor"), and Medeva PLC ("Parent") Gentlemen: We Understand That You Wish to Amend the Agreement to Provide for the Purchase of Common Stock by Parent at the Initial Closing. We Agree as Follows: 1. With Respect to the Initial Purchase and Sale of the Company's Common Stock Under the Agreement, Investor Hereby Assigns to Parent All of Investor's Rights and Obligations Under the Agreement. 2. With Respect to the Initial Purchase and Sale of the Company's Common Stock Under the Agreement, Parent Shall Have and Shall Perform All of Investor's Rights and Obligations Under the Agreement. 3. All Other Terms and Conditions of the Agreement Are Hereby Confirmed and Shall Continue in Full Force and Effect. <page> November 23, 1998 Page 2 Please Confirm Your Agreement With the Foregoing by Signing a Copy of This Letter in the Space Provided Below and Returning It to the Undersigned. Targeted Genetics Corporation, By: /S/ James A. Johnson Name: James A. Johnson Its: Vice President, Finance Agreed to and Accepted This 23rd Day of November, 1998. Medeva Pharmaceuticals, Inc. By: /S/ Mark Glyn Hardy Name: Mark Glyn Hardy Its: Assistant Secretary Medeva PLC By: /S/ John Murphy Name: John Murphy Its: Company Secretary Smg:smg
12/34/56
EX-1.5
from 8-K ~20 pages Credit Agreement
12/34/56
EX-1.4
from 8-K ~10 pages Common Stock Purchase Agreement
12/34/56